These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36945825)

  • 21. Subjective Medication Satisfaction With Antipsychotic Polypharmacy in a Naturalistic Inpatient and Outpatient Sample.
    Kikkert MJ; de Mooij L; de Koning M; Dekker J
    J Clin Psychiatry; 2021 Dec; 83(1):. PubMed ID: 34936243
    [No Abstract]   [Full Text] [Related]  

  • 22. Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan.
    Qiu H; He Y; Zhang Y; He M; Liu J; Chi R; Si T; Wang H; Dong W
    Aust N Z J Psychiatry; 2018 Dec; 52(12):1202-1212. PubMed ID: 30309245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance phase treatment of psychotic disorders in outpatients from Serbia - focus on long-term benzodiazepine use.
    Marić NP; Andrić Petrović S; Jerotić S; Ristić I; Savić B; Zebić M; Vuković V; Britvić D; Golubović O; Jakšić M; Jevđić K; Kolašinac Z; Lalović N; Mirković Ilić J; Nikolić S; Paunović Č; Pavlović Z; Pejović Nikolić S; Perović V; Popović J; Ranđić Avakumović V; Stojanović S; Tatarević M; Živković I; Voskresenski T; Jovanović N
    Int J Psychiatry Clin Pract; 2020 Sep; 24(3):315-321. PubMed ID: 32459564
    [No Abstract]   [Full Text] [Related]  

  • 24. Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
    Aly El-Gabry DM; Abdel Aziz K; Okasha T; Azzam H; Okasha A
    J Clin Psychopharmacol; 2018 Feb; 38(1):27-33. PubMed ID: 29210867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study.
    Malandain L; Thibaut F; Grimaldi-Bensouda L; Falissard B; Abenhaim L; Nordon C;
    Schizophr Res; 2018 Feb; 192():213-218. PubMed ID: 28558905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality risk from long-term treatment with antipsychotic polypharmacy vs monotherapy among adults with serious mental illness: A systematic review and meta-analysis of observational studies.
    Buhagiar K; Templeton G; Blyth H; Dey M; Giacco D
    Schizophr Res; 2020 Sep; 223():18-28. PubMed ID: 32948381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.
    Boskailo E; Malkoc A; McCurry DB; Venter J; Drachman D; Ramos GM
    Acta Med Acad; 2017 Nov; 46(2):133-144. PubMed ID: 29338277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.
    Saldaña SN; Keeshin BR; Wehry AM; Blom TJ; Sorter MT; DelBello MP; Strawn JR
    Pharmacotherapy; 2014 Aug; 34(8):836-44. PubMed ID: 24990538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
    Wu YH; Lai CY; Chang YS
    Psychogeriatrics; 2015 Mar; 15(1):7-13. PubMed ID: 25515355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
    Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
    Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study.
    Zhang SZ; Mu YG; Liu Q; Shi Y; Guo LH; Li LZ; Yang FD; Wang Y; Li T; Mei QY; He HB; Chen ZY; Su ZH; Liu TB; Xie SP; Tan QR; Zhang JB; Zhang CP; Sang H; Mi WF; Zhang HY
    BMC Psychiatry; 2019 Jul; 19(1):216. PubMed ID: 31291931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study.
    Misawa F; Shimizu K; Fujii Y; Miyata R; Koshiishi F; Kobayashi M; Shida H; Oguchi Y; Okumura Y; Ito H; Kayama M; Kashima H
    BMC Psychiatry; 2011 Jul; 11():118. PubMed ID: 21791046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic randomized open-label trial (SwAP trial).
    Shakir M; Willems AE; van Harten PN; van Lutterveld R; Tenback DE
    Schizophr Res; 2022 May; 243():187-194. PubMed ID: 35397249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in antipsychotics and other psychotropic drugs during a 30-month lifestyle intervention among outpatients with schizophrenia.
    Højlund M; Elliott AF; Madsen NJ; Viuff AG; Munk-Jørgensen P; Hjorth P
    Nord J Psychiatry; 2017 Nov; 71(8):598-604. PubMed ID: 28836471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polypharmacy in schizophrenia.
    Baandrup L
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):183-192. PubMed ID: 31908124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
    Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
    Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland.
    Solmi M; Lähteenvuo M; Correll CU; Tanskanen A; Tiihonen J; Taipale H
    Schizophr Bull; 2023 Jan; 49(1):78-89. PubMed ID: 36334051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia.
    Yasui-Furukori N; Shimoda K
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):208-210. PubMed ID: 32672006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.
    Tiihonen J; Suokas JT; Suvisaari JM; Haukka J; Korhonen P
    Arch Gen Psychiatry; 2012 May; 69(5):476-83. PubMed ID: 22566579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.